A large and time consuming part of your role will no doubt include writing detailed reports which face the scrutiny of the regulators. This short webinar being run by Dr Seema
30 Apr, 2015
Working in pharmacovigilance, I understand the challenge of all the different reports you’re required to submit, from the DSUR, RMP and PBRER. They all have similar sections
27 Mar, 2015
Risk Minimisation isn’t a new concept in pharmacovigilance yet it is rapidly evolving and it can be hard to stay on top of all the latest guidelines and developments.
Dr Seema Jaitly, Managing Director, Essjay Solutions, recently presented at the popular Back to Basics Pharmacovigilance course run by the Drug Safety Research Unit. A large
12 Feb, 2015
Valproic acid (VPA), di-n-propylacetic acid, was first synthetized in 1882 by Burton and used as a solvent for pre-clinical testing of lipophilic drugs (1). Its
02 Feb, 2015
It doesn’t matter how big or small your pharmaceutical company is, everyone has to go through the inspection process. It’s never going to be a pleasant experience but
02 Feb, 2015
Risk minimisation has become a crucial part of pharmacovigilance activities. Manufacturers and regulatory agencies are required to constantly monitor risks and adverse effects
I had the pleasure of attending the 4th Annual pharmacovigilance conference in Dubai on the 15th January. It was a very interesting conference that certainly opened my eyes to
28 Jan, 2015
The objective of a drug treatment is to deliver specific benefits to the patient. However, no drug is devoid of risk. Effective risk management ensures that expected benefits
Dr Seema Jaitly, founder at Essjay Solutions, will be presenting and facilitating a workshop at the ‘Back to Basics in Pharmacovigilance’ course held by the Drug Safety
